Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor

Inclusion Criteria: All Patients: * Patients ≥18 years of age at the time the ICF is signed; * Patients with a histologically or cytologically confirmed advanced solid tumor who, in the opinion of the Investigator, could potentially benefit from treatment with rucaparib * ECOG PS less than or equal to 2 * Adequate bone marrow and renal function Hepatically Impaired Patients (in addition): * Stable hepatic impairment as judged by the Investigator * Moderate Hepatic Impairment (NCI-ODWG criteria) during Screening Patients with Normal Hepatic Function (in addition): • Normal Hepatic Function (NCI-ODWG criteria) Exclusion Criteria: All Patients: * Prior treatment with chemotherapy, radiation, antibody therapy or other immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, or investigational drugs within 14 days prior to day 1 * Ongoing toxicity ≥ Grade 2 per Common Terminology Criteria for Adverse Events criteria (CTCAE version 4.03) * Prior treatment with any poly adenosine diphosphate ribose polymerase inhibitor * Arterial or venous thrombi (including cerebrovascular accident), myocardial infarction, admission for unstable angina, cardiac angioplasty, stenting or poorly controlled hypertension within the last 3 months prior to Screening * Pre-existing duodenal stent, and/or any gastrointestinal disorder or defect that would, in the opinion of the Investigator, interfere with absorption of rucaparib * Hospitalization for bowel obstruction within 3 months…